The Australian multicentre double‐blind comparative study of remoxipride and thioridazine in schizophrenia

Acta Psychiatrica Scandinavica

Volumn 90, Issue 5, 1994, Pages 358-365

  Keks, N ^a   McGrath, J ^b   Lambert, T ^c   Catts, S ^d   Vaddadi, K ^e   Burrows, G ^f   Varghese, F ^g   George, T ^h   Hustig, H ⁱ   Burnett, P ^j   Kerr, K ^k   Zorbas, A ^l   Hill, C ^m   Stedman, T ^b   Johnson, G ⁿ   Leibert, B ^d   Copolov, D ^m   Mackenzie, M ^o   Dillenbeck, C ^o  

^a ALFRED HOSPITAL   (Australia)

^b WOLSTON PARK HOSPITAL   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e MAROONDAH HOSPITAL   (Australia)

^f AUSTIN HOSPITAL   (Australia)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h THE PRINCE CHARLES HOSPITAL   (Australia)

ⁱ Glenside Hospital   (Australia)

^j Hillcrest Hospital   (Australia)

^k ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^l SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^m Royal Park Hospital   (Australia)

ⁿ Department of Microbiology and Infectious Diseases   (Australia)

^o Astra Pharmaceuticals ^*  (Australia)

more..

Author keywords

neuroleptic drug; remoxipride; schizophrenia; thioridazine

Indexed keywords

REMOXIPRIDE; THIORIDAZINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DYSTONIA; FEMALE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AUSTRALIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; REMOXIPRIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIORIDAZINE;

EID: 0027983982     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1994.tb01607.x     Document Type: Article

References (24)

1. Neuropharmacological and behavioural properties of remoxipride in the rat
2. A double‐blind comparative multi‐centre study of remoxipride and haloperidol in schizophrenia
3. A doubleblind comparative study of remoxipride and haloperidol in schizophrenia
4. Remoxipride and haloperidol in schizophrenia: a double‐blind multicentre study
5. Remoxipride and haloperidol in the acute phase of schizophrenia: a double‐blind comparison
6. A double‐blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia
7. A double‐blind comparative multicentre study of remoxipride and haloperidol in schizophrenia
8. A doubleblind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders
9. A double‐blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia
10. Experiences of long‐term treatment with remoxipride: efficacy and tolerability
11. A controlled doseranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial
12. A doubleblind comparative multicentre study of controlled release remoxipride, immediate release remoxipride and haloperidol in schizophrenia
13. A placebo‐controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation
14. New antipsychotics: classification, efficacy, and adverse effects
15. A doubleblind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia
16. Clinical Profile of remoxipride‐a combined analysis of a comparative double‐blind multicentre trial programme
17. The Brief Psychiatric Rating Scale
18. Treatment of schizophrenia
19. A self‐report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity
20. Quality of life of schizophrenic patients on indications and implications for new drug trials